Immune checkpoint inhibitor-related colitis in patients on immunotherapy for cancer

CONCLUSIONS: Future successful management of this form of colitis relies on our comprehension of the intricate interplay between tumoral and systemic immune responses to immune checkpoint inhibitors and innovative approaches to modify these responses, along with specific immune cell populations, to preclude immune-related adverse events while achieving antitumor therapeutic outcomes.PMID:38377034 | DOI:10.1093/ajcp/aqae002
Source: American Journal of Clinical Pathology - Category: Pathology Authors: Source Type: research